Physician profile
Bal K Gupta
NPI 1225041353
$3,547.27
in general payments reported to CMS, 2019-2025
15 companies · $418 in 2025
The $418 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $279 · 2020: $323 · 2021: $1,542 · 2022: $217 · 2023: $545 · 2024: $223 · 2025: $418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,185.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Validus Pharmaceuticals LLC | $1,686.81 | 2019-2025 | Equetro, Equetro, Raldesy |
| Abbvie INC. | $517.68 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $211.44 | 2019-2024 | Austedo Xr, Uzedy |
| Alkermes, INC. | $206.03 | 2023-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $182.74 | 2022-2025 | Rexulti, Nuedexta |
| Janssen Pharmaceuticals, INC | $141.86 | 2019-2025 | Invega Sustenna |
| Axsome Therapeutics, INC. | $114.01 | 2025 | Auvelity |
| Allergan, INC. | $99.22 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $93.71 | 2020-2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $86.84 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $73.08 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $56.43 | 2022-2023 | Quviviq |
| Sunovion Pharmaceuticals INC. | $37.64 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $22.39 | 2024 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $17.39 | 2023 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bal Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.